Tele: 561.316.3330
Breaking Medical Device News

Monday, September 20, 2021


HomeEXECUTIVESJim Dillon Joins FAST BioMedical Board of Directors: Provides Significant Commercialization Experience

Jim Dillon Joins FAST BioMedical Board of Directors: Provides Significant Commercialization Experience

November 3, 2020

Jim Dillon, former St. Jude Medical executive has been named to the FAST BioMedical board of directors.

Jim Dillon is a former St. Jude Medical and Abiomed executive, with significant experience capitalizing and commercializing first-in-class heart failure and cardiorenal syndrome technologies.

Jim Dillon has more than 30 years of expertise in driving innovation in healthcare. He is currently Chief Executive Officer of Reprieve Cardiovascular, a medical device company with a fluid management therapy for acutely decompensated heart failure patients. Dillon previously oversaw St. Jude Medical’s America’s product portfolio including Structural Heart and Heart Failure. In this role, Dillon led the integration of new high-growth technologies within strategic healthcare systems. At Abiomed, Dillon led US core business growth with a strategic focus on native heart recovery.

Dillon’s diverse portfolio of experience includes senior sales leadership, marketing and corporate strategy roles. He has successfully commercialized cardiac and renal technologies both in the U.S. and internationally. Dillon has built high-performance commercial teams generating hundreds of millions of dollars in revenue and resulting in billions of exit transaction value.

“Welcoming Jim to our Board is a pleasure,” said Joe Muldoon, CEO of FAST BioMedical. “His unique breadth of expertise in advancing technologies in heart failure and cardiorenal combined with his track record of capitalizing and positioning them to be the standard of care, through successful exit, fits perfectly with our strategy.”

“I am a champion of FAST BioMedical’s technology and am thrilled to join its Board of Directors,” said Dillon. “With so little technological advancement in tools to manage patient’s fluid status, there is a huge unmet medical need for this first-in-class innovation. I firmly believe it can enable precision medicine to save lives.”

Adding Dillon’s experience greatly prepares the company for its next steps.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy